Organization and Business (Details) $ in Thousands				1 Months Ended	12 Months Ended			65 Months Ended
	Oct. 01, 2019	Sep. 30, 2019	Mar. 29, 2019 USD ($)	Dec. 31, 2021	Dec. 31, 2021 USD ($) product segment shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2021 USD ($) shares
Subsidiary, Sale of Stock [Line Items]
Number of products launched | product					3
Number of reportable segments | segment					1
Shares of common stock repurchased (in shares) | shares					429,446	774,489	317,429
Cash paid for repurchases of common stock					$ 21,213	$ 34,999	$ 17,961
Cash paid for repurchases of common stock					$ 21,213	$ 32,037	$ 17,961
Accelerated Share Repurchase
Subsidiary, Sale of Stock [Line Items]
Shares of common stock repurchased (in shares) | shares								4,111,622
Cash paid for repurchases of common stock								$ 228,100
Vasopressin
Subsidiary, Sale of Stock [Line Items]
Marketing exclusivity term				180 days
Teva Pharmaceuticals
Subsidiary, Sale of Stock [Line Items]
Cash proceeds from license agreement			$ 9,000
Cephalon, Inc.
Subsidiary, Sale of Stock [Line Items]
Royalty payments if product is approved, percentage of net sales	30.00%	25.00%
Royalty revenue, percent of net sales threshold	32.00%